Physician

Irina Vancea, MD

According to 2025 Medicare claims, Irina Vancea, MD (NPI: 1205919750) practices nephrology in the Pueblo, CO market, with the plurality of this provider's patient population coming from Pueblo, CO. This provider's primary affiliated billing organization is SOUTHERN COLORADO NEPHROLOGY ASSOC PC (NPI: 1083642144; TIN: 841121886) and primary practice location at 81004-3878. Vancea is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Vancea's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 198 traditional Medicare patients, billed 2,606 HCPCS/CPT codes, and received $193,328 in Medicare payments. The top billing code was 90961 (Dialysis services, 2-3 physician visits per month (20 years or older)). Part D data shows 1,265 prescription claims across 200 beneficiaries totaling $158,962 in drug costs, led by Sevelamer Carbonate (Sevelamer Carbonate). DME data shows 113 claims. Open Payments data shows 8 records totaling $185. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $227,548 to $193,328. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $794,696 to $158,962. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	559	6,943	$227,548
2016	577	2,155	$255,909
2017	489	2,612	$286,578
2018	449	2,184	$268,429
2019	374	1,865	$245,893
2020	323	1,579	$202,313
2021	267	1,205	$171,275
2022	227	965	$150,570
2023	206	1,405	$155,337
2024	198	2,606	$193,328

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	226	1,684	$794,696
2016	278	1,455	$1,307,752
2017	257	1,603	$465,738
2018	217	1,434	$244,162
2019	227	1,654	$302,606
2020	223	1,607	$183,645
2021	212	1,346	$174,570
2022	214	1,406	$236,721
2023	216	1,483	$279,585
2024	200	1,265	$158,962

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	97	$43,765
2016	N/R	131	$11,836
2017	N/R	131	$3,194
2018	N/R	85	$1,952
2019	N/R	14	$245
2020	N/R	12	$213
2021	N/R	17	$218
2022	N/R	17	$276
2023	N/R	133	$3,555
2024	N/R	113	$2,227

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	36	206	$241
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	43	44	$141
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	54	89	$95
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	64	153	$65
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	36	282	$41

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sevelamer Carbonate	Sevelamer Carbonate	65	4,843	$26,791
Aranesp	Darbepoetin Alfa In Polysorbat	12	354	$25,788
Lokelma	Sodium Zirconium Cyclosilicate	14	718	$17,031
Calcium Acetate	Calcium Acetate	42	2,520	$4,690
Losartan Potassium	Losartan Potassium	144	11,745	$1,074

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	18	$1,318
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	47	$602
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$282
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	32	$25

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$185	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Irina Vancea, MD?

Tedicare shows public-source Medicare data for Irina Vancea, MD (NPI 1205919750), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Irina Vancea, MD have ACO affiliation data?

Irina Vancea, MD is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Irina Vancea, MD?

Irina Vancea, MD is linked to SOUTHERN COLORADO NEPHROLOGY ASSOC PC (billing NPI 1083642144) in the available physician profile data.

Does Irina Vancea, MD have Open Payments data?

Irina Vancea, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.